Document is current
Any future updates will be listed below
-
Authors
Cook, Joselle https://orcid.org/0000-0001-5335-9533
Gupta, Supriya https://orcid.org/0000-0001-5144-3467
Abdallah, Nadine https://orcid.org/0000-0001-9195-1589
Rees, Matthew https://orcid.org/0000-0001-8360-2952
Graham, Christopher
Ng, Lay She
Bansal, Radhika https://orcid.org/0000-0003-0964-098X
De Menezes Silva Corraes, Andre
Helms, Kristina https://orcid.org/0000-0001-7345-8045
Warsame, Rahma
Dingli, David https://orcid.org/0000-0001-7477-3004
Gonsalves, Wilson https://orcid.org/0000-0001-6890-969X
Kourelis, Taxiarchis https://orcid.org/0000-0001-8573-9434
Gertz, Morie https://orcid.org/0000-0002-3853-5196
Hayman, Suzanne
Leung, Nelson https://orcid.org/0000-0002-5651-1411
Kapoor, Prashant https://orcid.org/0000-0002-4342-364X
Hwa, Lisa
Fonder, Amie
Hobbs, Miriam
Bergsagel, Leif https://orcid.org/0000-0003-1523-7388
Yadav, Udit
Wiedmeier-Nutor, Erin
Chhabra, Saurabh https://orcid.org/0000-0001-9117-8696
Fonseca, Rafael
Ailawadhi, Sikander https://orcid.org/0000-0002-8377-8111
Parrondo, Ricardo https://orcid.org/0000-0002-9314-9933
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
- License Information
-
More Information
Article History
Received: 16 July 2025
Revised: 17 January 2026
Accepted: 25 February 2026
First Online: 30 March 2026
Competing interests
: RP: advisory board role for Sanofi Aventis and Astra Zeneca, research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline; SC: honoraria from Sanofi, Ascentage Pharma, Sobi, Legend Biotech, Pfizer, BMS and research funding from Johnson & Johnson, Takeda, C4 Therapeutics, Cynata Therapeutics, Cullinan Therapeutics, Abbvie, Ascentage Pharma, AstraZeneca; MG: personal fees from Ionis/Akcea, honorarium from Alnylym, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees for Data Safety Monitoring board from Abbvie & Arcellex, fees from Johnson & Johnson, Honoraria for Astra Zeneca, Medscape, Dava Oncology. Alexion; PK: Honoraria: Pharmacyclics, Sanofi, BeiGene, MustangBio, AstraZeneca, AbbVie. Consulting or Advisory Role: Sanofi. Research Funding: Amgen, Takeda, Sanofi, AbbVie, GlaxoSmithKline, Sorrento Therapeutics, Karyopharm Therapeutics, Regeneron, Ichnos Sciences, Bristol Myers Squibb/Celgene; PLB: Consultant: Oncopeptidfes. Salarius, Radmetrix, Omeros, CellCentric, AbbVie, Pfizer; SK: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech/Rocher, Abbvie, BMS/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accomodation and expenses: Abbvie, pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS/Celgene; SA: Consulting or Advisory Role: Takeda, BeiGene, GlaxoSmithKline, Sanofi, Pharmacyclics, BMS, Amgen, Janssen, Regeneron, Cellectar. Research Funding: Pharmacyclics, Janssen Biotech, Cellectar, BMS, Amgen, GlaxoSmithKline, AbbVie, Ascentage Pharma, Sanofi; RF: consultancy for AbbVie, Adaptive, Amgen, Apple, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific advisory board: Caris Life Sciences. Board of directors: Antengene. Patent for FISH in multiple myeloma; YL: advisory board role for Janssen, Sanofi, BMS, Regeneron, Genentech, Tesserae, Legend, NexT Therapeutics, steering committee for Janssen, Kite/Gilead, research funding from Janssen, BMS, scientific advisory board for Nonimmune, Caribou and sata safety monitor board for Pfizer. Others: No conflicts of interest to declare.
